We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · March 28, 2022

Survival Up With Bortezomib in T-Cell Lymphoblastic Lymphoma

No differences in EFS or OS seen with/without bortezomib overall or in patients with T-cell acute lymphoblastic leukemia

HealthDay

 

Further Reading